Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose immunoablation and autologous HSCT versus monthly IV cyclophosphamide in severe systemic sclerosis
2006-004598-83Phase 3Unknown
- Sponsor
- EBMT
- Start
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of cyclophosphamide in systemic sclerosis (SSc) (2 arms), sponsored by EBMT. Primary endpoint: Event-free survival. Status: unknown.
02
Drugs
cyclophosphamide
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on 2006-004598-83.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004598-83.